20 research outputs found
Resistance profile (first and second-line) for all MDR-TB cases (abbreviations: Hβ=β isoniazid, Rβ=β rifampicin, Eβ=β ethambutol, Sβ=β streptomycin, Zβ=β pyrazinamide, Eto β=β ethionamide, Amk β=β amikacin, Km β=β kanamycin, Cm β=β capreomycin, Ofx β=β of
<p>Resistance profile (first and second-line) for all MDR-TB cases (abbreviations: Hβ=β isoniazid, Rβ=β rifampicin, Eβ=β ethambutol, Sβ=β streptomycin, Zβ=β pyrazinamide, Eto β=β ethionamide, Amk β=β amikacin, Km β=β kanamycin, Cm β=β capreomycin, Ofx β=β ofloxacin).</p
Univariate and multivariate analyses to assess associations with rifampicin resistance among all, previously treated, and HIV positive culture positive TB cases.
<p>Univariate and multivariate analyses to assess associations with rifampicin resistance among all, previously treated, and HIV positive culture positive TB cases.</p
Prevalence of drug resistance using line probe assay (LPA) results, conventional culture-based DST and combined among new and previously treated culture-positive TB cases.
<p>Prevalence of drug resistance using line probe assay (LPA) results, conventional culture-based DST and combined among new and previously treated culture-positive TB cases.</p
Estimating the burden of rifampicin resistant tuberculosis in Khayelitsha.
<p>Estimating the burden of rifampicin resistant tuberculosis in Khayelitsha.</p
Second-line resistance among strains not defined as MDR-TB.
<p>Second-line resistance among strains not defined as MDR-TB.</p
Proportion of HIV-infected and -uninfected participants initiating TB treatment by time to treatment initiation for both study arms, ITT analysis.
<p>Xpert: solid line; routine: dashed line. (A) HIV-infected individuals (<i>p</i><0.001); (B) HIV-uninfected individuals (<i>p</i>β=β0.778).</p
TB treatment initiation, overall and by HIV status, in the Xpert and routine arms for both the ITT and per protocol analyses.
<p>TB treatment initiation, overall and by HIV status, in the Xpert and routine arms for both the ITT and per protocol analyses.</p
Clinical and demographic characteristics of participants by study arm for both the ITT and per protocol analyses.
<p>Clinical and demographic characteristics of participants by study arm for both the ITT and per protocol analyses.</p
Proportion of participants initiating TB treatment by time to TB treatment initiation for both study arms, ITT analysis (<i>p</i>β=β0.0042).
<p>Xpert: solid line; routine: dashed line.</p
Microbiological results by study arm for both the ITT and per protocol analyses.
<p>Microbiological results by study arm for both the ITT and per protocol analyses.</p